BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies us...
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies us...
Penny stocks to buy understandably offer many enticing attributes, not least of which is the potential for tremendous returns. Of course, the emphasis is on the word “potential....
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies usi...
Matinas BioPharma Hldgs (NYSEMKT: MTNB ) just reported results for the first quarter of 2024. Matinas BioPharma Hldgs reported earnings per share of -3 cents....
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer T...
Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025...
BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies usi...
BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a clinical-stage biopharmaceutical company ...
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript...
Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions...